OnKure Therapeutics (NASDAQ:OKUR) Shares Cross Above 50-Day Moving Average - Time to Sell?

OnKure Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Shares rose above their 50-day moving average: OnKure traded as high as $2.81 and last changed hands at $2.75, compared with a 50-day average of $2.71. Its 200-day average was higher at $3.59.
  • Analyst sentiment is mixed: MarketBeat reports an average rating of “Hold” and a consensus price target of $17.50; ratings include two Buys, one Hold, and one Sell. Weiss Ratings recently downgraded its assessment from “sell (d-)” to “sell (e+).”
  • Quarterly loss was narrower than expected: OnKure reported an EPS loss of $0.36, beating the consensus estimate of a $0.41 loss; analysts forecast a full-year EPS loss of $1.47.
  • Interested in OnKure Therapeutics? Here are five stocks we like better.

OnKure Therapeutics, Inc. (NASDAQ:OKUR - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $2.71 and traded as high as $2.81. OnKure Therapeutics shares last traded at $2.75, with a volume of 682,257 shares traded.

Analyst Ratings Changes

OKUR has been the subject of several research analyst reports. Weiss Ratings cut shares of OnKure Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, November 10th. Oppenheimer reissued an "outperform" rating and set a $14.00 price objective on shares of OnKure Therapeutics in a report on Friday, August 14th. Finally, HC Wainwright dropped their price objective on shares of OnKure Therapeutics to $21.00 and set a "buy" rating for the company in a report on Monday, July 20th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $17.50.

Check Out Our Latest Stock Report on OnKure Therapeutics

OnKure Therapeutics Stock Performance

The firm has a fifty day simple moving average of $2.71 and a two-hundred day simple moving average of $3.59. The firm has a market cap of $111.38 million, a PE ratio of -0.99 and a beta of 0.18.

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.05. Equities analysts forecast that OnKure Therapeutics, Inc. will post -1.47 EPS for the current fiscal year.

Institutional Investors Weigh In On OnKure Therapeutics

Several large investors have recently bought and sold shares of OKUR. Jump Financial LLC raised its stake in OnKure Therapeutics by 25.9% during the third quarter. Jump Financial LLC now owns 25,688 shares of the company's stock valued at $70,000 after purchasing an additional 5,288 shares in the last quarter. NewEdge Advisors LLC bought a new position in OnKure Therapeutics during the first quarter valued at $184,000. Empowered Funds LLC purchased a new position in shares of OnKure Therapeutics in the 3rd quarter worth $145,000. Bank of New York Mellon Corp purchased a new position in shares of OnKure Therapeutics in the 2nd quarter worth $329,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of OnKure Therapeutics in the 3rd quarter worth $315,000. Institutional investors own 90.98% of the company's stock.

About OnKure Therapeutics

(Get Free Report)

OnKure Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer. Its research centers on targeted therapies designed to address molecular changes that can drive tumor growth. The company's pipeline includes OKI-219, an investigational small-molecule therapy designed to selectively inhibit a mutant form of PI3Kα. OnKure has also worked on drug candidates targeting epigenetic mechanisms involved in cancer, reflecting its broader focus on developing treatments against specific cancer-related targets.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in OnKure Therapeutics Right Now?

Before you consider OnKure Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OnKure Therapeutics wasn't on the list.

While OnKure Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines